Evidence map›Paper›PMID 40504246›Full record

ReviewEuropean journal of clinical pharmacology2025

Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): a narrative review.

Francesco Ferrara, Lorenzo Martellone, Marcello Vaccaro, Adriana Coluccia, Manlio Scognamiglio, Roberto Langella, Andrea Zovi, Giacomo Polito

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesco FerraraPharmaceutical Department, Asl Napoli 3 Sud, Naples, Italy. ferrarafr@libero.it.ORCID http://orcid.org/0000-0001-9298-6783
Lorenzo MartelloneDepartment of Chemistry and Pharmaceutical Technologies, University of Rome "La Sapienza", Rome, Italy.
Marcello VaccaroPharmacy Department, Policlinico Umberto I, Rome, Italy.
Adriana ColucciaPharmacy Department, Policlinico Umberto I, Rome, Italy.
Manlio ScognamiglioPharmaceutical Department, Asl Salerno, Salerno, Italy.
Roberto LangellaItalian Society of Hospital Pharmacy (SIFO), SIFO Secretariat of the Lombardy Region, Milan, Italy.
Andrea ZoviDepartment of Health Prevention, Research and Emergencies, Ministry of Health, Rome, Italy.ORCID http://orcid.org/0000-0002-6528-2171
Giacomo PolitoPharmacy Department, Policlinico Umberto I, Rome, Italy.ORCID http://orcid.org/0009-0004-6158-1045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHealthcare-associated infections (HAIs) represent one of the most serious complications in medical care, with a substantial global burden. The emergence and spread of antibiotic resistance, particularly among multidrug-resistant organisms such as carbapenem-resistant Acinetobacter baumannii (CRAb), have significantly complicated infection management.

objectivesThe aim of this review is to provide an updated perspective on its clinical use and to explore novel therapeutic strategies for combating multidrug-resistant bacterial infections.

methodsA narrative review was performed in accordance with PRISMA 2020 guidelines, including real-world, comparative, and longitudinal observational studies that assessed cefiderocol efficacy, safety, and associated clinical outcomes.

resultsThe findings suggest that cefiderocol is a promising therapeutic agent for CRAb infections, demonstrating lower mortality rates compared to colistin-based regimens. Comparative studies also report a superior safety profile, particularly regarding reduced nephrotoxicity. Cefiderocol unique siderophore-mediated mechanism facilitates efficient bacterial uptake, enabling activity even against carbapenem-resistant strains.

conclusionsAlthough emerging evidence supports cefiderocol efficacy and safety, concerns persist about the potential for resistance development. Further randomized controlled trials are needed to clarify its role in the daily clinical practice and establish definitive treatment guidelines. In this context, the inclusion of reference intervals for resistance emergence during therapy is recommended, underscoring the need for vigilant monitoring throughout treatment.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsCefiderocolCephalosporinsCross InfectionCarbapenemsDrug Resistance, Multiple, BacterialHumansAnti-Bacterial AgentsCarbapenemsCefiderocolCephalosporinsAntibiotic resistanceCarbapenem-resistant Acinetobacter baumannii (CRAb)CefiderocolHealthcare-associated infections (HAIs)Multidrug-resistant antibiotic therapy

Identifiers

PMID40504246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.